debra of America Raises $600,000 at Annual Benefit; Honors Trailblazers in Epidermolysis Bullosa Community
Funds raised help advance EB research initiatives and directly support families and individuals living with EB.
- Funds raised help advance EB research initiatives and directly support families and individuals living with EB.
- At the benefit, debra honored several EB trailblazers for their research and therapeutic contributions as well as individuals living with the disease.
- Krystal Biotech was recognized for its work in developing VYJUVEK™ (beremagene geperpavec-svdt), the first FDA-approved treatment of Dystrophic Epidermolysis Bullosa (DEB).
- Epidermolysis Bullosa is a rare genetic disorder characterized by fragile skin that easily blisters or forms painful sores from minor friction or trauma.